Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
AssigneeSchering Corporation
InventorsMartin F. Haslanger, Edmund J. Sybertz, Jr.
Life of this patent
Estimating the term…
Abstract
The method of treating hypertension with neutral metalloendopeptidase (NMEP) inhibitors, NMEP inhibitors in combination with atrial peptides, and NMEP inhibitors in combination with angiotensin converting enzyme inhibitors, as well as pharmaceutical compositions therefor, are disclosed.
Claims16
A method for treating hypertension in mammals comprising administering to a mammal in need of such treatment an antihypertensive effective amount of a neutral metalloendopeptidase inhibitor in a pharmaceutically acceptable carrier.
A method for treating hypertension in mammals which comprises administering to a mammal in need of such treatment an antihypertensive effective amount of a combination of a neutral metalloendopeptidase inhibitor and an atrial peptide.
A pharmaceutical composition comprising an antihypertensive effective amount of a combination of a neutral metalloendopeptidase inhibitor and an atrial peptide in a pharmaceutically acceptable carrier.
A method for treating hypertension in mammals which comprises administering to a mammal in need of such treatment an antihypertensive effective amount of a combination of a neutral metalloendopeptidase inhibitor and an angiotensin converting enzyme inhibitor.
A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination to treat hypertension in mammals which comprises in one container a pharmaceutical composition comprising 10 to 500 mg per dose of a neutral metalloendopeptidase inhibitor and in a second container, a pharmaceutical composition comprising 0.001 to 1 mg per dose of an atrial peptide.
A kit comprising in separate containers in a single package pharmaceutical composition for use in combination to treat hypertension in mammals which comprises in one container a pharmaceutical composition comprising 10 to 500 mg per dose of a neutral metalloendopeptidase inhibitor and in a second container, a pharmaceutical composition comprising 5 to 50 mg per dose of an angiotensin converting enzyme inhibitor.
Dependencies are inferred from the claim text.